Mike Patten
About Mike Patten
Mike Patten is the Executive Director of Equity & Venture Capital at Bristol Myers Squibb, with extensive experience in pharmaceutical business development and strategic investments.
Title
Mike Patten is the Executive Director of Equity & Venture Capital at Bristol Myers Squibb.
Professional Background
Mike Patten has a diverse background in the pharmaceutical industry, with various roles at leading organizations. Before his current position at Bristol Myers Squibb, he served as BD & Global Alliances, Strategy & Business Development from 2019 to 2022. Prior to that, he worked at Celgene in Business Development & Global Alliances (2017-2019) and as Chief of Staff in Clinical, Finance, Business Planning, and Commercial Strategy (2010-2017). His earlier roles include Clinical Operations/Outsourcing at GlaxoSmithKline (2004-2010), Manager at EPA Euro Pharma GmbH's London Office (2003-2004), and Business Development at Quintiles (2000-2003).
Education and Expertise
Mike Patten holds an International Executive MBA from the EuroMBA Consortium (2012-2014) and an MSc in Pharmaceutical Medicine from the University of Surrey (2004-2010). He also has a BSc (Hons) in Pharmacology & Business from The University of Edinburgh (1996-2000). These qualifications underpin his extensive expertise in pharmaceutical investment and business development.
Strategic Achievements
In his role at Bristol Myers Squibb, Mike Patten led the multi-billion dollar strategic investment portfolio, significantly expanding the company’s innovative capabilities. His efforts have been instrumental in driving the growth and diversification of Bristol Myers Squibb's portfolio.
Board Directorship and Leadership
Mike Patten is a qualified Board Director, offering diverse perspectives to the pharmaceutical industry. His strategic acumen and collaborative approach have fostered innovation and growth within his teams, making significant contributions to the companies he has been a part of.